The earnings call reflects a company in transition with significant strides toward efficiency and profitability, highlighted by improved gross margins, a successful new sales model, and strategic FDA engagement. However, these positive developments are tempered by a decline in revenue due to the temporary suspension of sales in France and ongoing operating losses.

Company Guidance -

Q2 2025

During Allurion Technologies' first quarter earnings call for fiscal year 2025, the company provided a comprehensive update on its financial performance and strategic initiatives. Revenue for the quarter was reported at $5.6 million, with adjusted operating expenses of $10.1 million, reflecting a 45% decrease compared to the previous year. The adjusted net operating loss was $5.9 million, narrowing by 48% year-over-year, while the gross margin expanded to 75%, up from 73% the previous year and 45% in the prior quarter. The company outlined its five-pillar plan for 2025, which includes a new commercial strategy focusing on key geographies, gaining FDA approval for the Allurion Balloon, achieving profitability for the ex-U.S. business, scaling its AI product platform, and resuming commercialization in France. Allurion also highlighted its efforts to integrate GLP-1 therapies with its products, citing studies demonstrating significant weight loss and improved health metrics. The company maintains its revenue guidance of approximately $3 million, with a 50% reduction in operating expenses compared to 2024, and ended the quarter with $20 million in cash and cash equivalents.

Reduction in Operating Expenses

Adjusted operating expenses were reduced by 45% compared to the prior year, reflecting increased efficiency and progress toward profitability.

Expansion of Gross Margin

Gross margin expanded to 75% compared to 73% in the prior year and 45% in the previous quarter, driven by increased manufacturing efficiencies.

Successful B2B2C Model Implementation

The B2B2C sales model demonstrated over 40% growth quarter-over-quarter and year-over-year in clinics in Europe.

FDA Engagement and Approval Path

Completed pre-PMA meeting with FDA and expect to complete PMA submission by the end of June, with positive feedback on additional analyses.

Progress in France

Reengagement and re-training of clinics in France, with plans to resume commercialization in the second half of the year.

Strong Cash Position

Ended the first quarter with cash and cash equivalents of $20 million, providing a runway for achieving FDA approval and profitability.

Allurion Technologies (ALUR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALUR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 19, 2025	2025 (Q2)	-0.81 / -	-1.25	―	―	―
May 14, 2025	2025 (Q1)	-1.57 / 1.46	2.75	-47.02% (-1.29)	―
Mar 26, 2025	2024 (Q4)	-5.70 / -7.95	-10	20.50% (+2.05)	―
Nov 13, 2024	2024 (Q3)	-4.56 / -3.50	-13.408	73.90% (+9.91)	―
Aug 13, 2024	2024 (Q2)	-6.00 / -1.25	-73.968	98.31% (+72.72)	―
May 14, 2024	2024 (Q1)	-7.00 / 2.75	-10.8	125.46% (+13.55)	―
Mar 21, 2024	2023 (Q4)	-12.70 / -10.00	0.32	-3225.00% (-10.32)	―
Nov 13, 2023	2023 (Q3)	- / -13.41	1.962	-783.38% (-15.37)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALUR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$2.36	$2.92	+23.73%
Mar 26, 2025	$3.11	$3.12	+0.32%
Nov 13, 2024	$17.76	$13.08	-26.35%
Aug 13, 2024	$19.88	$19.46	-2.11%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Allurion Technologies, Inc. (ALUR) report earnings?

Allurion Technologies, Inc. (ALUR) is schdueled to report earning on Aug 19, 2025, Before Open (Confirmed).

What is Allurion Technologies, Inc. (ALUR) earnings time?

Allurion Technologies, Inc. (ALUR) earnings time is at Aug 19, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALUR EPS forecast?

ALUR EPS forecast for the fiscal quarter 2025 (Q2) is -0.81.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing